On February 20, 2019 Sunstar, a multi-national healthcare company based on oral care reported the acquisition from BMG Pharma S.p.A. of the innovative cancer supportive care product, GelX (Press release, SUNSTAR Americas, FEB 20, 2019, View Source [SID1234553908]). Through this acquisition Sunstar gains global distribution of this product line, expanding its position as a global leader in the development and commercialisation of oral healthcare products, mainly marketed under the GUM brand.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BMG Pharma S.p.A, an innovative specialty pharmaceutical company, will invest the proceeds from this transaction into the rapid development completion of a number of new patent protected products with topical, subcutaneous dermatology, osteoarthritis and oral care applications, which it will be able to offer to its network of global marketing partners.
Takeshi Kamigouchi, CEO of Sunstar Suisse SA, commented– "We are proud and excited to distribute the superior product GelX to make the difference in cancer patients’ oral conditions globally. Our purpose is to develop and provide products and services that promote mouth & body concept to extend people’s healthy lifespan and improve their quality of life. GelX is truly expected as a product that plays a key role that demonstrates we are the purpose driven company."
Marco Mastrodonato, CEO of BMG Pharma S.p.A., commented– "I have been partnering with Sunstar since 2002 with a win-win partnership in the oral care segment and at BMG are very proud to be the development and provider partner to a global oral care market leader. This is an important step for the company, bringing a strategic investment which represents a significant growth opportunity by allowing focus on the rapid completion of a number of products in our pipeline with unique propositions.